The MAPT H1 Haplotype Is a Risk Factor for Alzheimer's Disease in APOE ε4 Non-carriers

被引：22

作者：

Sanchez-Juan, Pascual ^{[1
,2
,3
,4
]}

Moreno, Sonia ^{[1
,3
,4
]}

de Rojaso, Itziar ^{[1
,3
,4
]}

Hernandez, Isabel ^{[1
,3
,4
]}

Valero, Sergi ^{[1
,3
,4
]}

Alegret, Montse ^{[1
,3
,4
]}

Montrreal, Laura ^{[1
,3
,4
]}

Garcia Gonzalez, Pablo ^{[1
,3
,4
]}

Lage, Carmen ^{[1
,2
,3
,4
]}

Lopez-Garcia, Sara ^{[1
,2
,3
,4
]}

Rodriiguez-Rodriguez, Eloy ^{[1
,2
,3
,4
]}

Orellana, Adelina ^{[1
,3
,4
]}

Tarraga, Lluis ^{[1
,3
,4
]}

Boada, Merce ^{[1
,3
,4
]}

Ruiz, Agustin ^{[1
,3
,4
]}

Abdelnour, C. ^{[1
,3
,4
]}

Aguilera, N. ^{[3
,4
]}

Alarcon, E. ^{[3
,4
,5
]}

Alegret, M. ^{[1
,3
,4
]}

Boada, M. ^{[1
,3
,4
]}

Buendia, M. ^{[3
,4
]}

Canabate, P. ^{[1
,3
,4
]}

de Rojas, I ^{[3
,4
]}

Diego, S. ^{[3
,4
]}

Espinosa, A. ^{[1
,3
,4
]}

Gailhajenet, A. ^{[3
,4
]}

Garcia Gonzalez, P. ^{[3
,4
]}

Gil, S. ^{[3
,4
]}

Guitart, M. ^{[3
,4
]}

Hernandez, I ^{[1
,3
,4
,12
]}

Ibarria, M. ^{[3
,4
]}

Lafuente, A. ^{[3
,4
]}

Martin, E. ^{[3
,4
]}

Mauleon, A. ^{[3
,4
]}

Monte-Rubio, G. ^{[3
,4
]}

Montrreal, L. ^{[3
,4
]}

Moreno-Grau, S. ^{[1
,3
,4
,12
]}

Moreno, M. ^{[3
,4
]}

Orellana, A. ^{[3
,4
]}

Ortega, G. ^{[1
,3
,4
]}

Pancho, A. ^{[3
,4
]}

Peleja, E. ^{[3
,4
]}

Perez-Cordon, A. ^{[3
,4
]}

Preckler, S. ^{[3
,4
]}

Rodriguez-Gomez, O. ^{[1
,3
,4
]}

Rosende-Roca, M. ^{[3
,4
]}

Ruiz, A. ^{[1
,3
,4
,12
]}

Ruiz, S. ^{[1
,3
,4
]}

Sanabria, A. ^{[3
,4
]}

Santos-Santos, M. A. ^{[3
,4
]}

机构：

[1] Minist Econ & Competitiveness, Natl Inst Hlth Carlos III, Ctr Networked Biomed Res Neurodegenerat Dis, Madrid, Spain

[2] Univ Cantabria, IDIVAL, Serv Neurol, Univ Hosp Marques de Valdecilla, Santander, Spain

[3] Univ Int Catalunya, Fundacio ACE, Inst Catala Neurociencies Aplicades, Res Ctr, Barcelona, Spain

[4] Univ Int Catalunya, Fundacio ACE, Inst Catala Neurociencies Aplicades, Memory Clin, Barcelona, Spain

[5] Univ Malaga, Sch Med, Dept Surg Biochem & Mol Biol, Malaga, Spain

[6] Univ Santiago de Compostela, Ctr Nacl Genotipado CEGEN PRB3 ISCIII, Grp Med Xenom, Santiago, Spain

[7] IDIS, CIBERER, Fdn Publ Galega Med Xenom, Santiago, Spain

[8] Hosp Clin San Carlos, Ctr Invest Biomed Red Diabet & Enfermedades Metab, Madrid, Spain

[9] Ctr Andaluz Estudios Bioinformat, Seville, Spain

[10] Hosp Univ Valme, Unidad Clin Enfermedades Infecciosas & Microbiol, Seville, Spain

[11] Univ Seville, CSIC, Hosp Univ Virgen del Rocio,Inst Biomed Sevilla, Unidad Trastornos Movimiento,Serv Neurol & Neurof, Seville, Spain

[12] Natl Inst Hlth Carlos III, Network Ctr Biomed Res Neurodegenerat Dis, Madrid, Spain

[13] Fundacio Recerca Biomed & Social Mutua Terrassa, Barcelona, Spain

[14] Univ Barcelona, Sch Med, Hosp Univ Mutua de Terrassa, Memory Disorders Unit,Dept Neurol, Barcelona, Spain

[15] Hosp Univ Cent Asturias, Lab Genet, Oviedo, Spain

[16] Inst Invest Biosanit Principado Asturias, Oviedo, Spain

[17] Hosp Univ Son Espases, Dept Neurol, Palma De Mallorca, Spain

[18] Hosp Clin Univ Virgen de la Arrixaca, Unidad Demencias, Murcia, Spain

[19] Hosp Univ & Politecn La Fe, Serv Neurol, Valencia, Spain

[20] Univ Seville, CSIC, Hosp Univ Virgen del Rocio, Unidad Demencias,Serv Neurol & Neurofisiol, Seville, Spain

[21] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, St Pau Biomed Res Inst, St Pau Memory Unit,Neurol Dept, Barcelona, Spain

[22] Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, Madrid, Spain

[23] Inst Invest Sanitaria Hosp la Paz, Madrid, Spain

[24] CIEN Fdn, Queen Sofia Fdn, Alzheimer Ctr, Madrid, Spain

[25] Inst Salud Carlos III, Madrid, Spain

[26] Hosp Univ Ramon y Cajal, Madrid, Spain

[27] Univ Basque Country, UPV EHU, Ctr Invest Lascaray, BIOMICs, Leioa, Spain

[28] Hosp Univ La Paz UAM, Neurol Serv, Madrid, Spain

[29] Andalusian Inst Neurosci, Alzheimer Res Ctr, Malaga, Spain

[30] Andalusian Inst Neurosci, Memory Clin, Malaga, Spain

[31] Univ Cantabria, Marques de Valdecilla Univ Hosp, IDIVAL, Neurol Serv, Santander, Spain

[32] Hosp Donostia San Sebastian, Donostia San Sebastian, Spain

[33] Fdn Formac & Invest Sanitarias Reg Murcia, Murcia, Spain

[34] Hosp Cabuenes, Serv Neurol, Gijon, Spain

[35] Fdn CITA Alzheimer, Ctr Invest & Terapias Avanzadas, Donostia San Sebastian, Spain

[36] Navarrabiomed, Pamplona, Spain

[37] Hosp Univ Cent Asturias, Serv Neurol, Oviedo, Spain

[38] Fundacio Pasqua Maragall, Barcelonasseta Brain Res Ctr, Barcelona, Spain

[39] CSIC, Inst Biomed Valencia, Unitat Genet Mol, Valencia, Spain

[40] Inst Invest Sanitaria La Fe, Unidad Mixta Neurol & Genet, Valencia, Spain

[41] Hosp Univ Santa Maria Lleida, Unitat Trastorns Cognitius, Inst Recerca Biomed Lleida, Lleida, Spain

[42] BT CIEN, Madrid, Spain

[43] Hosp Univ La Princesa, Madrid, Spain

[44] Hosp Clin Barcelona, Barcelona, Spain

来源：

FRONTIERS IN AGING NEUROSCIENCE | 2019年 / 11卷

关键词：

Alzheimer's disease; MAPT; APOE; genetic association; PROGRESSIVE SUPRANUCLEAR PALSY; TAU-GENE; CORTICOBASAL DEGENERATION; ASSOCIATION; PROTEIN; LOCUS;

D O I：

10.3389/fnagi.2019.00327

中图分类号：

R592 [老年病学]; C [社会科学总论];

学科分类号：

03 ; 0303 ; 100203 ;

摘要：

An ancestral inversion of 900 kb on chromosome 17q21, which includes the microtubule-associated protein tau (MAPT) gene, defines two haplotype clades in Caucasians (H1 and H2). The H1 haplotype has been linked inconsistently with AD. In a previous study, we showed that an SNP tagging this haplotype (rs1800547) was associated with AD risk in a large population from the Dementia Genetics Spanish Consortium (DEGESCO) including 4435 cases and 6147 controls. The association was mainly driven by individuals that were non-carriers of the APOE epsilon 4 allele. Our aim was to replicate our previous findings in an independent sample of 4124 AD cases and 3290 controls from Spain (GR@ACE project) and to analyze the effect of the H1 sub-haplotype structure on the risk of AD. The H1 haplotype was associated with AD risk (OR = 1.12; p = 0.0025). Stratification analysis showed that this association was mainly driven by the APOE epsilon 4 non-carriers (OR = 1.15; p = 0.0022). Pooled analysis of both Spanish datasets (n = 17,996) showed that the highest AD risk related to the MAPT H1/H2 haplotype was in those individuals that were the oldest [third tertile (>77 years)] and did not carry APOE epsilon 4 allele (p = 0.001). We did not find a significant association between H1 sub-haplotypes and AD. H1c was nominally associated but lost statistical significance after adjusting by population sub-structure. Our results are consistent with the hypothesis that genetic variants linked to the MAPT H1/H2 are tracking a genuine risk allele for AD. The fact that this association is stronger in APOE epsilon 4 non-carriers partially explains previous controversial results and might be related to a slower alternative causal pathway less dependent on brain amyloid load.

引用

页数：9

共 50 条

[1] A Systems View of the Differences between APOE ε4 Carriers and Non-carriers in Alzheimer's Disease
Jiang, Shan
Tang, Ling
Zhao, Na
Yang, Wanling
Qiu, Yu
Chen, Hong-Zhuan
[J]. FRONTIERS IN AGING NEUROSCIENCE, 2016, 8
[2] MAPT H1 Haplotype is Associated with Late-Onset Alzheimer's Disease Risk in APOE ε4 Noncarriers: Results from the Dementia Genetics Spanish Consortium
Pastor, Pau
Moreno, Fermin
Clarimon, Jordi
Ruiz, Agustin
Combarros, Onofre
Calero, Miguel
Lopez de Munain, Adolfo
Bullido, Maria J.
de Pancorbo, Marian M.
Carro, Eva
Antonell, Anna
Coto, Eliecer
Ortega-Cubero, Sara
Hernandez, Isabel
Tarraga, Lluis
Boada, Merce
Lleo, Alberto
Dols-Icardo, Oriol
Kulisevsky, Jaime
Luis Vazquez-Higuera, Jose
Infante, Jon
Rabano, Alberto
Angel Fernandez-Blazquez, Miguel
Valenti, Meritxell
Indakoetxea, Begona
Barandiaran, Myriam
Gorostidi, Ana
Frank-Garcia, Ana
Sastre, Isabel
Lorenzo, Elena
Pastor, Maria A.
Elcoroaristizabal, Xabier
Lennarz, Martina
Maier, Wolfang
Ramirez, Alfredo
Serrano-Rios, Manuel
Lee, Suzee E.
Sanchez-Juan, Pascual
[J]. JOURNAL OF ALZHEIMERS DISEASE, 2016, 49 (02) : 343 - 352
[3] The MAPT H1 haplotype is associated with reduced severity of Alzheimer disease pathology
Heather Wood
[J]. Nature Reviews Neurology, 2012, 8 (3) : 122 - 122
[4] Interaction between MAPT H1 and APOE4 in early Parkinson's Disease
Lambert, C.
Ahmed, Z.
Ostergaard, P.
Ricciardi, L.
Morgante, F.
Barrick, T.
Edwards, M.
[J]. MOVEMENT DISORDERS, 2018, 33 : S602 - S602
[5] Association analysis of the MAPT H1 haplotype and subhaplotypes in Parkinson's disease
Zabetian, Cyrus
Hutter, Carolyn M.
Factor, Stewart
Nutt, John
Higgins, Donald
Griffith, Alida
Roberts, John
Leis, Berta
Kay, Denise M.
Yearout, Dora
Montimurro, Jennifer S.
Edwards, Karen L.
Samii, Ali
Payami, Haydeh
[J]. NEUROLOGY, 2007, 68 (12) : A303 - A303
[6] Impact of the Mapt Haplotype H1 on Parkinson's Disease in the Greek Population
Bolbrinker, Juliane
Refenes, Nikolaos
Drakoulis, Nikolaos
Kreutz, Reinhold
[J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2009, 104 (06) : 512 - 512
[7] MAPT H1 HAPLOTYPE IS A RISK FACTOR FOR ESSENTIAL TREMOR AND MULTIPLE SYSTEM ATROPHY
Vilarino-Gueell, C.
Soto-Ortolaza, A. I.
Rajput, A.
Mash, D. C.
Papapetropoulos, S.
Pahwa, R.
Lyons, K. E.
Uitti, R. J.
Wszolek, Z. K.
Dickson, D. W.
Farrer, M. J.
Ross, O. A.
[J]. NEUROLOGY, 2011, 76 (07) : 670 - 672
[8] Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's disease
Zabetian, Cyrus P.
Hutter, Carolyn M.
Factor, Stewart A.
Nutt, John G.
Higgins, Donald S.
Griffith, Alida
Roberts, John W.
Leis, Berta C.
Kay, Denise M.
Yearout, Dora
Montimurro, Jennifer S.
Edwards, Karen L.
Samii, Ali
Payami, Haydeh
[J]. ANNALS OF NEUROLOGY, 2007, 62 (02) : 137 - 144
[9] Integrated Genomic Analysis Revealed Associated Genes for Alzheimer's Disease in APOE4 Non-Carriers
Jiang, Shan
Zhang, Chun-Yun
Tang, Ling
Zho, Lan-Xue
Chen, Hong-Zhuan
Qiu, Yu
[J]. CURRENT ALZHEIMER RESEARCH, 2019, 16 (08) : 753 - 763
[10] Body Mass Index Decrease Has a Distinct Association with Alzheimer's Disease Pathophysiology in APOE ε4 Carriers and Non-Carriers
Li, Anqi
Du, Jing
Cai, Yue
Chen, Xuhui
Sun, Kun
Guo, Tengfei
[J]. JOURNAL OF ALZHEIMERS DISEASE, 2023, 96 (02) : 643 - 655

← 1 2 3 4 5 →